Dose-dense chemotherapy for breast cancer.

about

Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study

P2860

Q34000716-B6880599-4F2F-48A0-AC35-9EE99D06E567

P2860

Dose-dense chemotherapy for breast cancer.

Item

http://www.wikidata.org/entity/Q38009885

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dose-dense chemotherapy for breast cancer.

@en

type

Item

label

Dose-dense chemotherapy for breast cancer.

@en

prefLabel

Dose-dense chemotherapy for breast cancer.

@en

P1476

Dose-dense chemotherapy for breast cancer.

@en

P2093

Banu Arun

http://www.w3.org/2001/XMLSchema#string

Soley Bayraktar

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

Theoretical concepts and the emerging role of taxanes in adjuvant therapy.

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

P304

261-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1524-4741.2012.01236.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22583196

http://www.w3.org/2001/XMLSchema#string

Dose-dense chemotherapy for breast cancer.

about

P2860

P2860

Dose-dense chemotherapy for breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698